Brought to you by:
‘Significant’ increase in atherectomy use in US largely driven by office-based procedures, VQI data show
In the United States, atherectomy use in peripheral vascular interventions (PVIs) “more than doubled” from 2010 to 2019, with office-based procedures a “major driver” of this increase. This is according to published U.S. data from the Vascular Quality Initiative (VQI),…
Disrupt PAD III observational study results confirm safety and effectiveness of IVL in complex calcified lesions
The final 1,373-patient cohort analysis from the Disrupt PAD III observational study (OS) demonstrates consistent intravascular lithotripsy (IVL; Shockwave Medical) outcomes in complex and challenging lesions across multiple peripheral vessel beds. Ehrin Armstrong, MD, from an interventional cardiologist from Adventist…
End-stage CLTI: Deep-vein arterialization procedure demonstrates amputation-free survival rate of 66% at six months
Six-month results from the PROMISE II trial of the LimFlow deep-vein arterialization system showed an overall amputation-free survival of 66%—“well above” the primary endpoint target of 54%, chief investigator Daniel Clair, MD, told the 2022 Vascular Interventional Advances (VIVA) meeting…
BEST-CLI attracts $3.3m funding injection to continue data analysis
The Novo Nordisk Foundation has made a $3.3 million contribution toward the BEST-CLI (Best endovascular vs. best surgical therapy in patients with critical limb ischemia) clinical trial, the Denmark-based entity has announced. The grant is set to be used by investigators…
CEA, TCAR ‘continue to show superior outcomes’ to transfemoral stenting
Researchers led by a vascular team in Indianapolis found that carotid endarterectomy (CEA) remains the most-used strategy in carotid revascularization, with CEA and transcarotid artery revascularization (TCAR) showing decreased odds of stroke or death compared to transfemoral carotid artery stenting…
SurVeil DCB demonstrates sustained durability of safety, efficacy endpoints in TRANSCEND
In the TRANSCEND clinical trial, the SurVeil drug-coated balloon (DCB; Surmodics) demonstrated “excellent efficacy and safety” out to 24-month follow-up. This is according to Kenneth Rosenfield, MD, from Massachusetts General Hospital in Boston, who presented the new data at Vascular…
New analysis: Four multicenter trials support primary use of drug-coated balloons over bare metal stents in femoropopliteal lesions
A patient-level, propensity-adjusted comparison of three-year results from a quartet of prospective, multicenter trials support the primary use of drug-coated balloons (DCBs) versus bare metal stents (BMS) in moderately complex femoropopliteal lesions, new data show. Lead researcher Mehdi Shishehbor, DO,…
‘Excellent’ three-year results presented for the BioMimics 3D stent in longer lesions
At the 2022 Vascular Interventional Advances (VIVA) meeting (Oct. 31–3 Nov. 3), Michael Lichtenberg, MD, from Arnsberg Clinic, Arnsberg, Germany, reported a subgroup analysis of the MIMICS-3D EU registry, revealing a headline finding of “excellent” three-year outcomes for the BioMimics…
Mechanical thrombectomy for DVT: Randomized data needed to boost growing evidence base
Two datasets presented during the late-breaking clinical trials session at The VEINS (Venous Endovascular Interventional Strategies) 2022 (Oct. 30–31) in Las Vegas—the latest results from CLOUT and a propensity score-matched analysis of CLOUT versus ATTRACT—bolster the evidence base for mechanical…
Abre stent data show ‘struggle to maintain patency’ among post-thrombotic syndrome patients
The Abre venous stent demonstrated three-year primary patency rates of 97.1%, 76.5% and 70.4% respectively for non-thrombotic iliac vein lesion (NIVL), acute deep vein thrombosis (DVT), and post-thrombotic syndrome (PTS) patient populations within the ABRE clinical study, a late-breaking session…